STOCK TITAN

Biodesix Announces Closing of Initial Public Offering

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Biodesix, Inc. (Nasdaq: BDSX) has successfully closed its initial public offering (IPO) of 4,000,000 shares at a price of $18.00 per share, raising approximately $72.0 million in gross proceeds. The shares began trading on The Nasdaq Global Market on October 28, 2020. Morgan Stanley and William Blair led the offering, with Canaccord Genuity and BTIG participating as managers. The offering's registration has been declared effective by the U.S. Securities and Exchange Commission. This announcement does not constitute an offer to sell or buy the securities.

Positive
  • Raised approximately $72.0 million in gross proceeds from IPO.
  • Shares began trading on The Nasdaq Global Market, enhancing visibility.
Negative
  • Potential dilution of existing shareholders due to new share issuance.

BOULDER, Colo.--()--Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds to Biodesix, before deducting underwriting discounts and commissions, were approximately $72.0 million. The shares began trading on The Nasdaq Global Market on October 28, 2020, under the symbol “BDSX.”

Morgan Stanley and William Blair acted as lead book-running managers for the offering. Canaccord Genuity acted as lead manager and BTIG acted as co-manager for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

A registration statement relating to the shares being sold in this offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

Contacts

Jeremy Feffer
jeremy@lifesciadvisors.com

FAQ

What was the IPO price for Biodesix (BDSX)?

The IPO price for Biodesix (BDSX) was $18.00 per share.

How many shares were offered in Biodesix's IPO?

Biodesix offered 4,000,000 shares in its IPO.

What are the total gross proceeds from Biodesix's IPO?

The total gross proceeds from Biodesix's IPO were approximately $72.0 million.

When did Biodesix begin trading on Nasdaq?

Biodesix began trading on Nasdaq on October 28, 2020.

Who were the lead underwriters for Biodesix's IPO?

Morgan Stanley and William Blair acted as the lead underwriters for Biodesix's IPO.

Biodesix, Inc.

NASDAQ:BDSX

BDSX Rankings

BDSX Latest News

BDSX Stock Data

184.74M
70.41M
47.12%
38.64%
0.29%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
LOUISVILLE